Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 30Rectal Neoplasms 21Esophageal Neoplasms 15Colorectal Neoplasms 15Pancreatic Neoplasms 12Lung Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Prostatic Neoplasms 10Adenocarcinoma Of Esophagus 9Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Sarcoma 7Esophageal Squamous Cell Carcinoma 7Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Urinary Bladder Neoplasms 4Inflammatory Breast Neoplasms 4Fallopian Tube Neoplasms 4Breast Neoplasms, Male 4Breast Carcinoma In Situ 4Brain Neoplasms 4Recurrence 3Neoplasm Metastasis 3Kidney Neoplasms 3Glioma 3Glioblastoma 3

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔